probenecid and Bone Cancer studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Research Excerpts

Excerpt	Relevance	Reference
"MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin."	7.80	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014)
"MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin."	3.80	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

probenecid and Bone Cancer

Research Excerpts

Research

Studies (1)

Authors

Other Studies

Authors	Studies
Ebert, R	1
Meissner-Weigl, J	1
Zeck, S	1
Määttä, J	1
Auriola, S	1
Coimbra de Sousa, S	1
Mentrup, B	1
Graser, S	1
Rachner, TD	1
Hofbauer, LC	1
Jakob, F	1